London – October 01, 2026 -- Curaleaf International's Que Medical Inhalation Device (QMID) has become the first cannabis inhalation device to secure registration from Australia's Therapeutic Goods Administration, clearing the way for clinicians to prescribe a standardized-dosing device in a market that has treated more than one million patients since 2016.

Cary, N.C. – October 01, 2026 -- SAS and North Carolina State University have launched the SAS Think & Do Tank, a two-year pilot research partnership applying data and AI to human health, nutrition and environmental resilience challenges, 50 years after SAS originated from an NC State agricultural research project.

Salt Lake City – October 01, 2026 -- Banner Capital has formed Seaway Group and signed a definitive agreement to acquire three medical device manufacturing businesses -- Seaway Plastics Engineering, MME Group and Wright Engineered Plastics -- in a transaction expected to close in the fourth quarter of 2026, subject to customary closing conditions.

San Diego – October 01, 2026 -- Avimer Bio and structural biologists at Spain's National Cancer Research Centre (CNIO) have published computational methods for building self-assembling protein cages with atomic precision, detailed in the Journal of the American Chemical Society (JACS). The study tackles a long-standing design challenge: predicting protein architecture when building blocks bend during assembly.

Sarasota, Fla. – October 01, 2026 -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) will send CEO Kelvin Cooper, Ph.D., to three separate industry conferences this month, placing the clinical-stage antimicrobial developer in front of both investors and infectious-disease specialists within an eight-day window.

Boston – October 01, 2026 -- HoneyNaps, an AI-based sleep health technology company, has completed registration as a clinical research organization (CRO) with South Korea's National Enterprise for Clinical Trials (KoNECT), broadening its role in pharmaceutical and medical device trials worldwide.

Tel Aviv, Israel – October 01, 2026 -- Lutris Pharma reported that its topical B-Raf inhibitor LUT014 achieved Treatment Success in 71.8% of patients with EGFR inhibitor-induced acneiform rash, compared with 38.5% on placebo (p=0.003), in updated Phase 2 data presented at the 35th EADV Congress in Vienna.

Paramus, N.J. – October 01, 2026 -- NS Pharma, Inc. reported 5-year efficacy and safety data showing its investigational therapy brogidirsen maintained or improved motor function in Duchenne muscular dystrophy (DMD) patients amenable to exon 44 skipping, with zero treatment discontinuations across the study period.

Dallas – October 01, 2026 -- Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has accepted and granted priority review to Nanoscope Therapeutics' New Drug Application for MOGENRY (sonpiretigene isteparvovec, MCO-010), an optogenetic gene therapy for inherited retinal dystrophies (IRDs). If approved by the Ministry of Health, Labour and Welfare, MOGENRY would become the first disease-agnostic treatment available to IRD patients in Japan, a condition caused by mutations across more than 250 genes that leads to progressive photoreceptor loss and blindness.

Dublin – – October 01, 2026 -- Ensera, a global CDMO specializing in commercialization support for injectable drug programs, has launched the Ensera Alliance Network, uniting device platform and fill-finish specialists to streamline the commercialization of drug-device combination products.